Viral oncolysates

Whole melanoma cells Autologous cells Allogeneic cells Haptenized cells Melanoma cell lysates Viral oncolysates Shed melanoma cell supernatant Defined antigen vacciness Gangliosides (GM2, GD2)... 

This author is highly rewarded just by being able to see this achievement, inasmuch as it was in his laboratory at the M.D. Anderson Hospital in Houston, TX (vide infra), where both naturally immune, or viral oncolysate vaccine-induced small compact lymphocytes (later immune T cells), or large granular lymphocytes... 

Oncolytic viruses in IFN-deficient tumor cells. In the Type I IFN-deficient tumor cells innate immunity fights oncolytic vimses, but vaccination with viral oncoly-sates induced strong anti-tumor cell immune reactions. Hilary Koprowski presented a lecture at the young M.D. Anderson Hospital in 1957 on viral oncolysate therapy... 

Figure 44 Viral Oncolysate Cancer Vaccines Immunized the Hosts against Fused Viral Envelope and Host Cell Membrane Proteins. Reference Appendix 2, Explanations to the Figures...

The relapse rates of resected deep primary, or regional lymph node metastatic melanoma could be reduced by post-operative therapy with lENa (10-15 % reduction), or with viral oncolysate vaccines especially, NDV oncolysates were effective (decades long durable remissions induced). Preventively, the Morton allogeneic melanoma cell-BCG Canvax vaccines did not work in prospectively designed clinical trials, but it induces immune reactions and reduces circulating tumor cell numbers. Oncolytic viruses directly injected into melanoma tumors induce partial remissions. ... 

DM head Clifton Howe mobilized private donors in support of the viral oncolysate project. The Hospital s Surveillance Committee approved the project with the support of Jan van Eys, head of the MDACC Department of Pediatrics, chairman of the Surveillance Committee. Staff physician medical oncologists-hematologists Nicholas Papadopoulos and Carl Plager joined this author for the clinical conduct of... 

Horvath JC, Horak A, Sinkovics JG, Pritchard M, Pendleton S, Horvath E. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine. Acta Microbiol Immunol Hung. 1999 46 1-20. 

Sinkovics JG. Immunotherapy of sarcomas with viral oncolysates. J Am Med Assoc. 

Sivanandham M, Wallack MK. Viral oncolysates. In DeVita VT, Heilman S, Rosenberg SA editors. Biological therapy of cancer. 2nd ed. Philadelphia J.B. Lippincott Company 1995. p. 659-667. 

---